CORONA · Healthcare · Drug Manufacturers - General
Composite scorecard: 48/100 — Quality 82 · Valuation 0
| Share price | ₹2,046.10 |
| P/E ratio | 67.6 |
| P/B ratio | 16.7 |
| ROE | 26.2% |
| ROCE | 29.0% |
| Dividend yield | 0.49% |
| Book value | ₹122.12 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,403 Cr | ₹185 Cr | 21.0% |
| 2025 | ₹1,196 Cr | ₹149 Cr | 20.0% |
| 2024 | ₹1,014 Cr | ₹90 Cr | 15.0% |
| 2023 | ₹884 Cr | ₹85 Cr | 14.0% |
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.